Tag Archives: ovarian

The ovarian “biological clock” and other reproductive health metaphors science got wrong

There is a lot scientists still don’t know about the female reproductive system. They don’t know enough about how to treat the most common vaginal infection, bacterial vaginosis. They don’t have good solutions for many people suffering from endometriosis, a common and sometimes incredibly painful condition where tissue similar to what grows inside the uterus grows elsewhere in the body. They still have a lot of questions about what menopause does to a body.

So a few years ago, Rachel Gross, a science reporter who focuses on reproductive health, set out to write a book about the mysteries of the female reproductive system. But as she dove into the research, she started to wonder about the phrase she was using — the phrase “female reproductive system.”

First, not everyone with the organs she was researching was female. She was speaking to nonbinary people, intersex people, trans people; all people for whom this anatomy was relevant and intimate.

Also, the idea that these organs — the clitoris, the vagina, even the ovaries — were only playing a role in reproduction started to feel reductive. Of course, these organs are involved in baby-making, but, she says, “I was finding that they were doing so much else, not just sexual stuff, which is huge and often overlooked, but they were participating in immunity and protection and regeneration.”

On Unexplainable — Vox’s podcast that explores big mysteries, unanswered questions, and all the things we learn by diving into the unknown — Gross talks about one of these organs: the ovaries. She tells us a familiar story: that the ovaries are “biological clocks” that only lose eggs, without ever gaining any back. But then, she walks us through new research that questions that idea, suggesting that the ovaries may be able to generate new eggs using stem cells.

And, as Gross explains, this new way of understanding and imagining the ovaries might lead to new fertility treatments — but also, potentially, new ways to treat some of the health effects associated with menopause, like loss of bone density.

In her book, Vagina Obscura: An Anatomical Voyage, Gross finds many examples of metaphors like the ovarian “ticking clock,” or even whole stories about various pelvic organs, that have stymied science and maybe even kept scientists from solving some of the big questions about these organs.

“When you study the human body, even though the human body is not changing, you really see what you expect to see … and you kind of just blur out the rest,” she says.

I asked Gross to walk me through some more examples from her book. What follows is our conversation, edited for clarity and length.

Byrd Pinkerton

What’s an example of an organ we’ve told an incorrect story about and how it misguided science?

Rachel Gross

So one big example is the clitoris. It has been called a minuscule phallus or an underdeveloped penis or a tiny nub for hundreds and hundreds of years. And science has sort of minimized it in many ways, from literally omitting it in anatomical textbooks to just not studying 90 percent of it, which is under the surface.

It took a female urologist to say, “Wait, the research on the female side is a lot less rigorous than the male side. We haven’t looked at all the nerves, the erectile bodies.”

She found out that the clitoris has these roots and these bulbs that actually hug the vagina and swell with blood and become erectile just like the penis. So you have the exact same erectile tissues, you have the head — or the glans clitoris — which is the part you can see and touch. But then you also have a shaft that goes back into the body and you have bulbs and kind of arms that flow back into the pelvis. And all of these are made up with the same erectile tissues as the penis.

These things are super important for women undergoing surgery in this area who don’t want their nerves cut off.

If you look at it [the clitoris] as a homologous organ [to the penis], you come to such a different conclusion than it’s a tiny phallus or a little nub that’s hard to find.


This video digs into another misleading story scientists told for decades — this one about the role the sperm and egg play in fertilization.

Byrd Pinkerton

[At the beginning of her book, Rachel Gross describes a personal experience. She got a persistent vaginal infection, and her gynecologist recommended that she put boric acid in her vagina. The poison would kill a lot of the organisms in her vagina, including, hopefully, the one causing her problems.

Boric acid is also used as a rat poison, however, so the harshness of the treatment surprised Gross. And as she dived into the research, she realized that a new way of imagining the vagina might lead to more effective, less poisonous treatments.]

You talked about putting this boric acid pill into your vagina. Is that treatment based on any outdated story or a metaphor around the vagina that people are reconsidering?

Rachel Gross

So I think there’s been a strong attitude toward the vagina of like … it should be pure, it should be clean, it should be sterile. And from that you get all of these vaginal cleansing products. What blew my mind was looking at the vaginal microbiome as this teeming ecosystem of protection instead.

Byrd Pinkerton

What is the vaginal microbiome?

Rachel Gross

So, you’ve heard of the gut microbiome, the specific bacteria that help maintain digestive health.

Byrd Pinkerton

Yep.

Rachel Gross

Well, your vagina also has a microbiome, and it’s actually really unique to humans. It’s a mildly acidic environment created by mostly bacteria called lactobacilli, but also other bacteria, some viruses, and fungi. And they all live in harmony and protect you from invaders and kind of keep this liminal space between you and not-you healthy. It’s up against whatever gets up there, whether that is tampons, semen, birth control, jade eggs, other stuff you put in there … like your vagina is responding, protecting you and reaching a new equilibrium.

Byrd Pinkerton

Interesting. So if you’re thinking of that space as like a garden that fends off invaders, it does feel like you would reimagine putting rat poison in the middle of your garden.

Rachel Gross

Exactly. If you reimagine it as a garden and it’s fine to have weeds and different species in a garden, then it’s not about stripping it of life, which is what the rat poison does. It’s about cultivating the right mix. And that has led to innovations in vaginal microbiome transplants or probiotics that could kind of terraform the vagina. All these different ideas, it’s not clear that all of them will work, but there’s just so many smarter and more imaginative ways to think of having a healthy vagina.

Byrd Pinkerton

So, do we know anything about our bodies? Or is it all just sort of stories we’re telling ourselves that are shaping the directions that we’re taking?

Rachel Gross

I do think that we know a lot about bodies and we use that knowledge very practically in medicine to heal them and make things better. But there’s a lens of language that just directs the questions we’re asking and what we consider interesting and worthwhile. So could you swing that lens a little to the left, to the part that’s all blurred out, and focus on that? And what would you see?

Byrd Pinkerton

How do you swing the lens and reshape what we know about the reproductive system?

Rachel Gross

By introducing new people with new backgrounds into science and having them ask their questions and be interested in what they’re interested in. And for a long time, we’ve had a very similar lens.

You had people that were centering the male body as representing something and looking at the female body as an afterthought or as something that was mainly involved in reproduction. That’s mainly the interesting difference between types of bodies. So yeah, my whole book is about how once you get new voices and people in science, the whole lens changes in really exciting ways.

Read original article here

Doctor told her sex was painful because of her age. It turned out to be ovarian cancer

Mara Kofoed, 45, was diagnosed with ovarian cancer in December 2021 after months trying to figure out vague and seemingly unrelated symptoms. She found doctors dismissed them at every turn and didn’t connect them to a tumor. It took a visit to an emergency room to finally get answers. Kofoed, who lives in Hudson Valley, New York, shared her story with TODAY.

It was the biggest shock of my life to find out that I had ovarian cancer. I would have suspected maybe breast cancer because my grandmother had it, but ovarian cancer was very, very off the radar.

Women need to be trained on this more. We know about breast cancer, but almost no one could rattle off the symptoms of ovarian cancer — I couldn’t have rattled them off. There are all these minor, little things, and it’s very hard for people to put it all together. The doctor wasn’t putting it together either.

In 2017, I started feeling a little pain during sex. That was the earliest thing. Another early symptom was a little bit of a different sensation around my urethra. I thought, “It feels like a UTI, but it’s different.” It felt like something was pressing on my bladder.

There was also a change in my urination patterns — I was getting up in the night to go pee, which was new and different for me. I was going to pee more frequently during the day, too.

I had general fatigue without an explanation. I also suffered from constipation.

Fatigue was one of the symptoms.

In May of 2021, I started noticing my waist was thicker. I’m very thin and slender normally, so I just noticed a thickness around my belly. I was skinny in other areas, so it looked like I had gained a little bit of weight, but only below the ribs.

I did hear that bloating was a symptom of ovarian cancer, but it’s such a vague symptom. I still wasn’t even thinking cancer. I didn’t know enough about what to look for. The bloating is happening because the tumors are growing and there is fluid surrounding them, a condition called ascites.

Bloating is a very misleading way to describe it. We think of bloating as gas that’s from eating something. But people don’t connect that to the ovaries, so it needs a different language. It’s a thickened abdomen area that’s persistent, later growing into a distended belly.

Related: Woman with ovarian cancer who urged others to know symptoms dies at 43

I started having little pains in the ovaries — little pinches and twinges. I also had a couple of episodes with extreme ovarian pain where I was leaning over, grabbing the countertop, telling my husband something is very wrong.

I saw the first gynecologist I could get in with, which wasn’t until November 30, 2021. I told him about all of the symptoms and my belly was very large, but it wasn’t like I went in there going, “I’m ready to get checked for ovarian cancer.” I still had no idea what was wrong with me. I wasn’t stringing these things together, I didn’t know they were all related.

He ignored almost all of the symptoms that I mentioned, but focused on one. He leaned back in his chair and said to me, “Women your age stop wanting sex and so they get dry.” He was focusing on the pain-during-sex part.

This photo shows Kofoed’s distended belly. (Courtesy Mara Kofoed)

He didn’t seem concerned about my belly size. I wanted to get a scan, but he said, “You don’t need a scan.” I left that appointment completely traumatized because of what he said to me, how he ignored me and dismissed what I was saying. His office sent me a document in the mail that said the Pap test was clear and “We’ll see you in a year.”

A week and a half after that appointment, on December 10, I went to a local urgent care off the highway on a Friday night because I didn’t think I could get through the weekend. The distended belly was so extreme that it severely affected my walking, breathing, eating, drinking, sleeping, sitting and going to the bathroom. It was adding pressure to every organ — so intense, I thought I might die. It was one of the most painful and scary things I’ve ever experienced.

I told the nurse all of my symptoms. She looked at my belly and took it seriously. She knew right away this was not normal and said, “You need to go to the ER tonight and get a CT scan.”

At the ER, doctors came back in after the scan and said they found a mass. I needed to see an oncologist immediately.

It turned out to be stage 3C ovarian cancer. Each ovary had a tumor — 12 centimeters on one side, 6.5 centimeters on the other. There were two smaller tumors on the rectum and bladder that were about 2 centimeters. Just a week and a half earlier, the doctor examined me and missed that.

Kofoed had to undergo chemotherapy. (Courtesy Mara Kofoed)

I underwent a debulking surgery on December 28th, 2021. They took out the ovaries, tubes, uterus, cervix and omentum, which is a lining that holds everything together.

I also received six treatments with two chemotherapy drugs. Today, I’m doing very well. I took very good care of myself during chemo treatments.

If I had waited a year for my next appointment, as that doctor’s office advised, it would have meant death. I wouldn’t have lasted a year.

One of the most important things for women to look at is their thoughts. Are you saying to yourself: “This is weird. This isn’t normal. I wonder what this is?”

The biggest messages of all with this disease is: If there is a symptom that is persistent, that keeps coming back or maybe it doesn’t go away at all, that is very concerning.

This interview was edited and condensed for clarity.

Read original article here

We Finally Have a Genetic Link Between Ovarian Cancer And This Common Disorder

Scientists have found a genetic link and a potentially causal relationship between endometriosis and some types of ovarian cancer.

The absolute risk of an endometriosis patient developing cancer is still very low, but these overlapping genetic markers could help researchers understand and treat both illnesses better in the future.

 

“We don’t want women with endometriosis to worry, but rather we want them to be aware and know that the purpose of this study was to increase our understanding of both of these diseases by understanding the genetic link between them,” explains molecular bioscientist Sally Mortlock, from the University of Queensland, Australia.

Endometriosis is a highly common and notoriously underdiagnosed condition. It occurs when cells similar to the lining of the uterus grow elsewhere in the body, sometimes causing pain or infertility.

Similar to other female pain conditions, endometriosis, or ‘endo’ for short, has been historically overlooked by medicine, and thanks to that setback, today, we still know very little about it, including how it’s caused.

Recent research suggests endo holds a strong genetic component, often clustering in families. Epidemiological studies have also shown those with endo are more likely to develop ovarian cancers later in life.

To further investigate the relationship between these two conditions, researchers in Australia gathered together data from several genome-wide association studies.

In the end, they found 19 genetic locations in female DNA that appear to predispose people to endo while also predisposing them to epithelial ovarian cancer (which is the kind that develops in the lining outside the ovary).

 

“Overall, studies have estimated that 1 in 76 women are at risk of developing ovarian cancer in their lifetime, and having endometriosis increases this slightly to 1 in 55,” says Mortlock.

We still don’t know how to predict which endo patients are more likely to develop ovarian cancers, but Mortlock’s recent research gives us a few clues.

The study used genomic data from several large and recent meta-analyses on endometriosis and epithelial ovarian cancer. Unlike previous studies, however, the authors were able to causally associate the genetic components of endometriosis with some types of ovarian cancer.

In simple terms, this means researchers found the genes responsible for endometriosis were driving the development of tissue that increase the risk of developing ovarian cancer, but not the other way around.

This directionality suggests that endometriosis and epithelial ovarian cancer (EOC) are biologically related, and that “a genetic variant’s effect on endometriosis is likely to cause its effect on EOC for the variants highlighted in this study”, according to the authors.

The genetic regions shared by endometriosis and EOC could help experts figure out what mechanisms are driving this causal relationship and what biological pathways might contribute to the risk.

 

Such research could provide potential drug targets and treatment options for both illnesses, halting their progression.

In the current study, for instance, some shared genetic variants were found in regions known to host hormone-responsive genes.

This suggests hormone regulation might help block the causal pathway between endometriosis and a type of EOC known as clear cell ovarian cancer (CCOC), which is associated with abnormal tissue growth outside the uterus.

The authors also note that cell adhesion pathways were “significantly enriched” for some genetic variations shared between endo and CCOC. This suggests the ability of endometriosis lesions to adhere to tissue might be an important part of disease development for both illnesses.

Endometrioid ovarian cancer (ENOC) was also similarly associated with endometriosis, and, to a lesser extent, high-grade serous ovarian cancer (HGSOC), which is one of the deadliest human cancers with few predictive biomarkers.

Some of the genetic markers for endo and EOC identified in the current study are also shared with other reproductive diseases, like polycystic ovary syndrome and uterine fibroids.

The authors, therefore, suspect the “perturbation of underlying pathways important for the development and regulation of the reproductive and endocrine systems may predispose women to a variety of diseases”, depending on their genetic and environmental risk factors.

 

Endometriosis itself is not cancerous, but over the years, researchers have compared the way endometrial lesions metastasize, spread, invade and damage tissue to that of cancerous cells.

Some case studies have even shown that on very rare occasions, endometrial lesions can transform into malignant tissue.

There are still so many avenues to explore when it comes to understanding endometriosis, but genetic studies like these can help experts whittle down the numerous options in front of them, pushing future research in the right direction.

The study was published in Cell Reports Medicine.

 

Read original article here

In Mice, a Potential New Treatment Eradicates Ovarian And Colorectal Cancer in Days

An experimental new type of cancer treatment has yielded some impressive results in mice: the eradication of advanced-stage ovarian and colorectal cancer in the animals as little as six days.

 

The new therapy has only been tested in mice so far, so let’s not get too excited just yet. However, the early signs are promising, and human clinical trials could be underway by the end of the year.

The treatment involves tiny ‘drug factory’ beads that are implanted into the body and deliver a continuous, high dose of interleukin-2 (IL2) – a natural compound that enlists white blood cells in the fight against cancer.

“We just administer once, but the drug factories keep making the dose every day, where it’s needed until the cancer is eliminated,” says bioengineer Omid Veiseh from Rice University in Texas.

“Once we determined the correct dose – how many factories we needed – we were able to eradicate tumors in 100 percent of animals with ovarian cancer and in seven of eight animals with colorectal cancer.”

The bead-like ‘drug factories’ held by Amanda Nash (left) and Omid Veiseh. (Jeff Fitlow/Rice University)

Interleukin-2 is one of a group of immune system-triggering proteins called cytokines. Although cytokines are already used in cancer treatment for melanoma and renal carcinoma, but the problem scientists have is getting cytokines to fight tumors effectively while avoiding dangerously high levels of inflammation elsewhere in the body, causing dramatic side effects. 

In this study, the beads were placed in the peritoneum, a sac-like lining around the intestines, ovaries, and other abdominal organs. That enables the drugs to specifically target the cancer without burdening the body in terms of volume or weight.

 

The dose of interleukin-2 given by these drug factories would be too toxic if delivered through an IV drip, but here it works because the high concentrations are focussed on the tumor. The concentration of the protein elsewhere in the body seems to be around 30 times lower than near the tumor, according to tests.

Each bead has an outer cell made of hydrogel which shields the cytokine-producing cells, protecting them from attack. These beads are recognized as foreign objects by the surrounding immune system, but not as immediate threats, which enables them to do their work. They can then be programmed to turn off automatically.

“We found foreign body reactions safely and robustly turned off the flow of cytokine from the capsules within 30 days,” says Veiseh. “We also showed we could safely administer a second course of treatment should it become necessary in the clinic.”

The drug factory beads can potentially be adopted for cancers elsewhere in the body, as long as there’s a lining where they could house them, and they could be tweaked to deliver different types of drugs, the researchers say. It’s a flexible system as well as an innovative one.

What’s more, the drugs that are being used here have already been approved as safe for use in clinical trials, which should speed up the process. The final treatment should be minimally-invasive and relatively straightforward to administer.

“In this study, we demonstrated that the ‘drug factories’ allow regulatable local administration of interleukin-2 and eradication of tumors in several mouse models, which is very exciting,” says Amir Jazaeri, a professor of gynecologic oncology and reproductive medicine at the University of Texas. “This provides a strong rationale for clinical testing.”

The research has been published in Science Advances.

 

Read original article here

Tennis legend Chris Evert reveals ovarian cancer diagnosis

Tennis legend Chris Evert revealed Friday she was diagnosed with stage 1C ovarian cancer.

Evert, 67, said in a statement she felt “very lucky” doctors caught the cancer early.

CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM

Chris Evert provides analysis at the Wimbledon Tennis Championships at the All England Lawn Tennis and Croquet Club July 8, 2021 in London.
(Karwai Tang/WireImage)

“I wanted to share my stage 1 ovarian cancer diagnosis and the story behind it as a way to help others. I feel very lucky that they caught it early and expect positive results from my chemo plan,” she said. “Thanks to Chris McKendry for her friendship and for co-writing this very personal story with me. And thanks to all of you for respecting my need to focus on my health and treatment plan. You will see me appear from home at times during ESPN’s coverage of the Aussie Open.”

In a story for ESPN expanding on her diagnosis, Evert said the cancer was discovered following a preventative hysterectomy. The cancer has not been detected anywhere else in her body.

“I’ve lived a very charmed life. Now I have some challenges ahead of me. But I have comfort in knowing the chemotherapy is to ensure that cancer does not come back,” Evert said.

AUSTRALIAN OPEN FAVORITES SOUND OFF ON NOVAK DJOKOVIC SAGA: ‘ALL THIS COULD HAVE BEEN AVOIDED’

Chris Evert speaks during the induction ceremony at the International Tennis Hall of Fame in Newport, R.I., Saturday, July 12, 2014.
(AP Photo/Michael Dwyer, File)

Evert, who won 18 Grand Slam tournaments and is an analyst for ESPN, was a former No. 1 in the WTA rankings and was inducted into the International Tennis Hall of Fame in 1995.

Her sister, Jeanne Evert Dubin, died from ovarian cancer in February 2020 at age 62.

“Be your own advocate. Know your family’s history. Have total awareness of your body, follow your gut and be aware of changes,” Evert said. “Don’t try to be a crusader and think this will pass.”

Fellow tennis legend Billie Jean King tweeted thoughts of encouragement to Evert.

Chris Evert competes in the 1988 French Open.
(Dimitri Iundt/Corbis/VCG via Getty Images)

CLICK HERE TO GET THE FOX NEWS APP

“You are one of a kind, and there are so many who love you,” King tweeted.

The Associated Press contributed to this report.

Read original article here

Chris Evert, Tennis Hall of Famer, Says She Has Ovarian Cancer

The former tennis star Chris Evert, an 18-time Grand Slam singles champion, has an early form of ovarian cancer, she said Friday in a story posted on ESPN.com.

The stage 1C cancer was detected after a preventive hysterectomy, and it has not spread elsewhere in her body, according to the story. Ms. Evert, 67, who began the first of six rounds of chemotherapy this week, is an analyst for ESPN.

The cancer was removed during the hysterectomy, and there is a greater than 90 percent chance it won’t return, according to the story.

“I’ve lived a very charmed life,” Ms. Evert said in the story. “Now I have some challenges ahead of me. But, I have comfort in knowing the chemotherapy is to ensure that cancer does not come back.”

A representative for Ms. Evert did not immediately reply to an email late Friday.

Ms. Evert is one of the most celebrated players in tennis history. She became the first player, male or female, to win 1,000 singles matches and was ranked first or second in the world from 1975 to 1986, according to the International Tennis Hall of Fame.

Dr. Joel Cardenas, a doctor for Ms. Evert, said in the story that an early diagnosis is more likely if a patient is current on doctor visits, understands her family history and has a good relationship with her gynecologist.

“Women should know the risk factors, too — endometriosis, history of breast cancer and infertility are among them,” he said. “The average age for ovarian cancer diagnosis is 63.”

Genetic testing and counseling are encouraged if a patient has a family history of ovarian cancer, Mr. Cardenas said.

Ms. Evert’s younger sister, Jeanne Evert Dubin, also a professional tennis player, died of ovarian cancer in February 2020 at age 62. Ovarian cancer can run in families, and one’s risk is increased if a mother, sister or daughter has had the disease, according to the American Cancer Society.

Ms. Dubin was with Ms. Evert as the pair rushed through an airport in October 2017 when the older sister noticed Ms. Dubin was out of breath, according to the ESPN story. Shortly after that, a doctor detected ovarian cancer in Ms. Dubin. It was in a late stage and had spread.

“When I go into chemo, she is my inspiration,” Ms. Evert said. “I’ll be thinking of her. And she’ll get me through it.”

Read original article here

FDA approves ‘glowing tumor’ drug to help surgeons identify ovarian cancer cells

Cytalux (pafolacianince), a drug that binds to ovarian cancer tissue and glows when exposed to fluorescent light, has been approved by the U.S. Food and Drug Administration (FDA) to help surgeons detect ovarian tumors during surgical procedures in patients.

A Purdue University spokesperson told Fox News that Philip Low, Purdue University’s Presidential Scholar for Drug Discovery, invented the drug. Low described in a press release that when a surgeon turns on the near-infrared light during the surgery, “those lesions light up like stars against a night sky.”

“While many surgeries result in complete resection of all cancer tissue, a substantial fraction unfortunately leave buried or concealed tumor tissue behind, often resulting in recurrence of the cancer and sometimes even death,” Low told Fox News.

EXPERIMENTAL DRUG BOOSTS IMMUNOTHERAPY TREATMENT OF PANCREATIC CANCER IN MICE

He added: “To help prevent the latter outcomes, we have designed a cancer-targeted fluorescent dye that homes specifically to cancer cells that express a folate receptor and causes them to fluoresce brightly upon illumination with near infrared light.”

Low explained that cancer cells require folate, a B vitamin, to divide rapidly, so he invented the drug that tagged a folate compound with a fluorescent dye. The drug is administered intravenously to a patient before surgery.

Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

“Cancer cells have an enormous appetite for this vitamin,” Low said in the release, “and we exploited their greed for folic acid by attaching a fluorescent dye to it.”

Low told Fox News that when the illumination occurs, the surgeon can locate and resect malignant lesions that he or she might otherwise have overlooked during the surgery.

A spokesperson for the University of Pennsylvania Health System told Fox News that while Purdue’s Phil Low synthesized the drug, Researchers at the school were the principal investigators for the Phases 1, 2 and 3 of trials and found promising results. Dr. Sunil Singhal, along with colleagues at the Center for Precision Surgery in the Abramson Cancer Center at the University of Pennsylvania in partnership with On Target Laboratories, led one of the largest clinical trial sites in the country for Cytalux, according to the spokesperson.

FDA TO SCRUTINIZE UNPROVEN CANCER DRUGS AFTER 10-YEAR GAP

“By using a fluorescent dye that binds to cancer cells, making them glow during surgery, surgeons can identify and resect as much of a patient’s tumors as possible and improve prognosis,” Singhal, director of the Center for Precision Surgery at the Abramson Cancer Center at the University of Pennsylvania said in release. 

In the randomized, multi-center Phase 3 study, 134 adult women who were administered Cytalux intravenously prior to surgery, were evaluated under both fluorescent and normal light. The release stated that in the group, 27% had at least one cancerous lesion detected that was not discovered by standard inspections through sight or touch during surgery.

The university researchers said this new technology provides surgeons with a guide that goes beyond what is seen with the naked eye or touch, especially when the lesions are small, according to the release. They also stated that it will help surgeons remove cancerous tissue in a more precise manner, while sparing the removal of healthy tissue. The newly approved dye also helps detect cancerous lymph nodes.

“Lighting up cancer, which helps to identify lesions that may be difficult to find — especially in the presence of scar tissue or other organ damage — enables more complete identification and surgical removal of cancer that could have otherwise been missed,” Janos L. Tanyi, principal investigator at the University of Pennsylvania’s clinical trial site for Phase 2 and Phase 3 studies, said.

CLICK HERE TO GET THE FOX NEWS APP

Tanyi, who is also an associate professor of obstetrics and gynecology in the Perelman School of Medicine at the university also said that this new FDA approval will offer promise for improved outcomes in patients with ovarian cancer, who face a high risk of recurrence after initial treatment.

Scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton.
(Reuters)

The investigators said in the release that only 20% of ovarian cancers are detected early because it is either asymptomatic or the symptoms mimic common gastrointestinal, bladder or bowel issues. By the time most women receive their diagnosis, the investigators said the disease has advanced, and most patients require surgery to remove tumors along with chemotherapy, according to the report.

Cytalux is the first tumor-targeted fluorescent agent for ovarian cancer approved by the FDA.

On Target Laboratories will release the drug under the brand name Cytalux.

Read original article here

‘Don’t dismiss your pain’: Neuroscientist, 44, dying of ovarian cancer makes it her last mission to save other women

Dr Nadia Chaudhri is a Canadian neuroscientist. Earlier this month, her Twitter account reached 100,000 followers, and she marked the occasion by telling them she was dying.

“Now that I have 100K followers, I want to talk about #OvarianCancer,” she wrote. “Specifically my gritty story.”

Dr Chaudhri, 44, is a psychology professor at Concordia University in Montreal. She is also a terminal cancer patient at a Canadian hospital, where she is receiving palliative care for “high-grade serous epithelial, platinum-resistant ovarian cancer.” In simpler terms, as she puts it, she will never come home.

But Dr Chaudhri is not going quietly. Instead, she has used her “gritty story” to issue an urgent warning to others: “Know your bodies.”

Due to her illness, the professor is no longer giving interviews. But on Twitter, she’s offered a painfully detailed account of what’s happened to her.

“The goal is awareness,” she said. “I hope you find this narrative informative.”

Dr Chaudhri says she first started feeling ill in January 2020. She was “tired, had vague abdominal pain, severe lower back pain & a mild increase in frequency to urinate.”

Her doctor diagnosed her with a urinary tract infection, and treated her with antibiotics and a laxative. For a time, she seemed to get better, but in mid-February her symptoms flared up again. Her doctor prescribed more antibiotics.

“Come March, the pandemic struck,” Dr Chaudhri wrote. “By now my abdomen was bloated and I was in moderate pain. My bowel movements had changed too so I kept taking stool softeners. I couldn’t see my doctor because of the pandemic. I was incredibly tired but I chalked it up to the pandemic.”

In April she was put on yet another course of antibiotics. All this time, she says, her symptoms were not typical of a UTI, but her doctor continued to believe that was the problem.

Meanwhile, Dr Chaudhri underwent two endovaginal ultrasound scans, and showed the second one to her uncle, a gynaecologist. He recommended getting a blood test for ​​CA 125, CA 19 and CEA – “cancer markers.”

Her CA came back at about 26 times the normal level.

The next day Dr Chaudhri visited the clinic of a top gynaecologist in Montreal, where she did another ultrasound.

“Four days later I met her in clinic,” she recalled. “She said 24 of 25 doctors in the tumour board said I had cancer.”

On 10 June, six months after she first started feeling ill, Dr Chaudhri had a laparotomy – a major abdominal surgery to check for cancer.

“They cut me open from sternum to pubic bone,” she wrote. “Indeed, I had cancer.”

Four weeks later, she started chemotherapy. For a number of months, she seemed to improve. Then, in December, her CA began to rise up again.

“It crept up slowly,” she said. “But because this started happening within 6 months of the end of chemo it meant that my cancer had a label: platinum resistant. It had learned to evade the platinum based chemo.”

Things got worse from there. She developed a bowel obstruction, which disqualified her from a clinical trial she’d been on for one medicine. She tried another drug, which didn’t work, and then another, which worked and then stopped working. She was running out of options.

“Between March and now I’ve had more bowel obstructions than I care to count,” Dr Chaudhri wrote on 13 September. “The most recent one hasn’t opened. It is why I have moved to palliative care. I can’t poop or pass gas. I can’t eat. I’ve been on IV fluids for 2 weeks.”

At this point, Dr Chaudhri is no longer trying to “beat” her cancer. It’s not that she lost a battle, she says. It’s simply that the treatments didn’t work.

Tragically, Dr Chaudhri believes that outcome is partly due to how much time was lost between her first symptoms and her diagnosis of cancer. More knowledge is needed, she says – among both doctors and patients.

“The bottom line is that ovarian cancer research is underfunded,” she wrote. “We also need more awareness of symptoms because early detection improves prognosis dramatically.”

Dr Chaudhri’s warning is as simple as it is urgent: “Know your bodies. Pay attention to fatigue and changes in bowel/urinary tract movements. Make sure you understand all the words on a medical report. Do not dismiss your pain or malaise. Find the expert doctors.”

As for herself, Dr Chaudhri says her final journey has been frightening, but also “filled with brightness and love.” She has spent precious time with her husband and son, who is in first grade, and with “friends and a tribe of supporters who have bolstered me into the clouds.”

“I will feast in my new life and welcome everyone to my forest table,” she says. “I am not afraid.”



Read original article here

Mom dying of ovarian cancer shares what she wants women to know about the deadly disease

A mom who is in the final stage in herfight against ovarian cancer is sharing the details of her “gritty story” to help educate and inform women.

Dr. Nadia Chaudhri, a 44-year-old neuroscientist and professor from Montreal, Canada, has been battling Stage 3 ovarian cancer for the past year, undergoing a hysterectomy and several rounds of chemotherapy.

In May, Chaudhri, the mom of a 6-year-old son, was hospitalized again and learned the cancer had returned, forcing her to tell her son that her cancer was now terminal.

She shared on Twitter this month that she is now receiving palliative care and preparing herself and her family for the reality that she will not be “coming home from this hospital visit.”

Chaudhri is using her time in the hospital to send a powerful message to women about ovarian cancer, which causes more deaths each year than any other gynecologic cancer in the United States, according to the Centers for Disease Control and Prevention (CDC).

“Ovarian cancer comes in many forms & treatments are more advanced for some forms than others, but he bottom line is that ovarian cancer research is underfunded,” she wrote. “We also need more awareness of symptoms because early detection improves prognosis dramatically.”

Chaudhri’s six-month journey to an ovarian cancer diagnosis began in January 2020 when she started to feel symptoms like fatigue, abdominal pain, lower back pain and changes in urination.

PHOTO: Dr. Nadia Chaudhri, 43, of Montreal, is pictured with her 6-year-old son. (Dr. Nadia Chaudhri)

After being treated with three courses of antibiotics for what was misdiagnosed as a urinary tract infection, Chaudhri said she continued to have symptoms like fatigue and abdominal pain.

The topic of cancer only came up once she underwent a second ultrasound. She showed the results to her uncle, a gynecologist, who suggested a blood test for cancer markers, which led to further tests, according to Chaudhri.

“Two weeks later I had a laparotomy. They cut me open from sternum to pubic bone. Indeed, I had cancer,” she wrote. “They removed all of the visible disease in a four hour surgery. It happened on June 10 2020. About 6 months after I first started ‘feeling bad.'”

Chaudhri went on to describe the details of her treatment for ovarian cancer, including multiple rounds of chemotherapy and several attempts at clinical trials.

“Know your bodies,” Chaudhri urged women. “Pay attention to fatigue and changes in bowel/urinary tract movements. Make sure you understand all the words on a medical report. Do not dismiss your pain or malaise. Find the expert doctors.”

What women should know about ovarian cancer

Ovarian cancer originates in the ovaries, which make female hormones and produce eggs, or in the nearby areas of the fallopian tubes and the peritoneum, the tissue that lines your abdominal wall, according to the CDC.

A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 78, while her lifetime chance of dying from ovarian cancer is about 1 in 108, according to the American Cancer Society (ACS).

Ovarian cancer can affect females of all ages and races but is most common in women ages 63 and older and is more common in white women than Black women, according to the ACS.

MORE: Newer hormonal birth control linked to lower ovarian cancer risk: Study

While early signs of ovarian cancer can be vague, the main symptoms are abdominal pain or pelvic pain, bloating and an increase in urination, according to Dr. Jennifer Ashton, ABC News chief medical correspondent and a board-certified OBGYN.

“If these symptoms or others last for more than half the month you want to alert a gynecologist and, again, talk about the fact that it could possibly be ovarian cancer,” Ashton said on “Good Morning America” in June, after Christiane Amanpour, chief international anchor for CNN, announced her own ovarian cancer diagnosis.

PHOTO: Ovarian cancer symptoms are described here. (ABC)

It is particularly important for women to pay attention to symptoms of ovarian cancer and speak openly with their doctor because there is currently no reliable way to screen for the disease, according to Ashton.

In some cases, targeted use of pelvic scans and sonograms or a CA-125 blood test may be used to detect ovarian cancer, but additional testing is “not one size fits all and it is not recommended for all women,” explained Ashton.

Treatment for ovarian cancer usually involves a combination of surgery and chemotherapy, according to the CDC.

While there is no known way to prevent ovarian cancer, there are things associated with lowering the risk of getting ovarian cancer, including using birth control for five or more years, having given birth, breastfeeding, having had a hysterectomy, having had your ovaries removed and having had a tubal litigation, according to the CDC.

Mom dying of ovarian cancer shares what she wants women to know about the deadly disease originally appeared on goodmorningamerica.com

Read original article here